Pancreatic neuroendocrine tumor

Disease · 2 studies in the Atlas

Pancreatic neuroendocrine tumor - a cancer where mTOR drives growth; everolimus more than doubled progression-free survival (RADIANT-3), an FDA-approved indication.

A rare pancreatic tumour type. A type of pancreatic cancer driven partly by mTOR signaling. Everolimus more than doubled the time before the tumor progressed in a major clinical trial, and it's now an approved treatment.

RADIANT-3 showed progression-free survival benefit; mTOR-pathway mutations are recurrent in this histology.

TL;DR. Pancreatic neuroendocrine tumor appears in 2 curated studies in Oliver's mTOR Atlas: 2 in people (2 human studies). It has 1 interaction in the curated pathway model.

In the pathway model

1 interaction in the curated mTOR pathway model. Each row is a claim with the evidence behind it; the evidence code is the kind of study, not its quality.

Interaction	Mechanism	Evidence	Studies
Everolimus inhibits Pancreatic neuroendocrine tumor mechanism: clinical-outcome · this link in full · on the map table	In a trial, everolimus more than doubled the time before advanced pancreatic neuroendocrine tumours got worse. RADIANT-3: progression-free survival more than doubled in advanced pancreatic neuroendocrine tumours. RADIANT-3: progression-free survival more than doubled in advanced pancreatic neuroendocrine tumours. Holds under: One phase 3 trial (RADIANT-3, n=410) in advanced pancreatic neuroendocrine tumours. The result applies to that disease, stage and dose, and it is a progression-free survival result. shown in people · settled in the literature	H	YAO2011

Evidence at a glance

Evidence	What it means	Studies
H	Human study	2

Studies

Year	Evidence	Study
2026	H	[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. WALTER2026 Phase 3 open-label RCT (n=309, 2:1): 177Lu-edotreotide gave longer PFS than everolimus (23.9 vs 14.1 months; HR 0.67) with fewer grade 3-4 treatment-related adverse events (18% vs 40%), supporting PRRT in early lines for progressive SSTR-positive GEP-NETs.
2011	H	Everolimus for advanced pancreatic neuroendocrine tumors (RADIANT-3) YAO2011 A phase 3 RCT (n=410) that made everolimus a standard treatment for pancreatic neuroendocrine tumors. It more than doubled progression-free survival (11.0 vs 4.6 months, a 65% reduction in risk of progression/death) with mostly mild side effects. Another FDA-approved indication built on blocking mTOR.

Related entities

Cite this page

ShowHide

Barton, O. (2026). Pancreatic neuroendocrine tumor [Entity page]. In Oliver's mTOR Atlas [Data set]. https://mtor-atlas.org/disease/pancreatic-neuroendocrine-tumor/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_disease_pancreatic_neuroendocrine_tumor,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}: Pancreatic neuroendocrine tumor},
  howpublished = {Entity page in a data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/disease/pancreatic-neuroendocrine-tumor/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?